Transplantation in MM - general conclusion

GOLD STANDARD

UP TO DATE THE MOST EFFECTIVE TREATMENT OPTION FOR PTS. AT LEAST TO age 60-65 years

Second AT for pts. who did not achieved CR after first transplantation

CZECH MYELOMA GROUP
ČESKÁ MYELOMOVÁ SKUPINA

AGE DISTRIBUTION OF MM PTS. AT THE TIME OF DIAGNOSIS

Age ranges	0 - 67 y	68 - 74 y	75+ y
• part from total No.	48 %	28%	27%

LESS THAN 50%

OF NEWLY DIAGNOSED PTS. ARE ELIGIBLE

FOR TRANSPLANTATION MAINLY DUE TO AGE LIMIT AND/OR STANDARD CONTRAINDICATIONS

CZECH MYELOMA GROUP
ČESKÁ MYELOMOVÁ SKUPINA

EPIDEMIOLOGIC DATA
&
NUMBER OF PTS. AVAILABLE TO THE TRANSPLANT TRIALS

Country	*Number of Cases*
Czech Rep.	575
Slovakia	275

Total Population

in CR and SR

is

15 MIL.

CZECH MYELOMA GROUP
ČESKÁ MYELOMOVÁ SKUPINA

EPIDEMIOLOGIC DATA
&
NUMBER OF PTS. AVAILABLE TO THE TRANSPLANT TRIALS

Country	*Number of Cases*	*Age reduction 50%*	*Indication 70%/ 30%*	*Exclusion crit.10-30%*
Czech Rep.	550	→ 250	→ 175	→ 130
Slovakia	275	→ 130	→ 40	→ 30

TOTAL OF 160 PTS./YEAR

=20% OF ALL PTS. (155/825)

CZECH MYELOMA GROUP
ČESKÁ MYELOMOVÁ SKUPINA

EPIDEMIOLOGIC DATA
&
NUMBER OF PTS. AVAILABLE TO THE TRANSPLANT TRIALS

Country	*Number of Cases*	*Age reduction 50%*	*Indication 70%/ 30%*	*Exclusion crit.10-30%*
Czech Rep.	550	→ 250	→ 175	→ 130
Slovakia	275	→ 130	→ 40	→ 30

Total Population in CR and SR is 15 MIL.

TOTAL OF 160 PTS./YEAR

=20% OF ALL PTS. (155/825)

125 PTS./YEAR IN THE TRIALS

= 75%

CZECH MYELOMA GROUP
ČESKÁ MYELOMOVÁ SKUPINA

Randomized Trials of CMG

Clinical Trial 4W (1996)



Dropt out during

INDUCTION phase in the trial 4W was

25%

Clinical Trial CMG 2002



Dropt out during

INDUCTION phase in the trial CMG 02 is

24%

CZECH MYELOMA GROUP
ČESKÁ MYELOMOVÁ SKUPINA

AGE DISTRIBUTION OF MM PTS. AT THE TIME OF DIAGNOSIS

Age ranges	0 - 67 y	68 - 74 y	75+ y
• part from total No.	48 %	28%	27%



AGE DISTRIBUTION OF MM PTS. AT THE TIME OF DIAGNOSIS

EPIDEMIOLOGIC DATA & NUMBER OF PTS. AVAILABLE TO THE TRANSPLANT TRIALS

Country	Number of Cases	Age reduction 50%	Indication 70%/ 30%	Exclusion crit.10-30%
Czech Rep.	550	→ 250	→ 175	→ 130
Slovakia	275	→ 130	→ 40	→ 30

Total Population in CR and SR is 15 MIL.

TOTAL OF 160 PTS./YEAR

=20% OF ALL PTS. (155/825)

↓

125 PTS./YEAR IN THE TRIALS

= 75%

) - 67 y	68 - 74 y	75+ y
48 %	28%	27%



The Indication of AT for all available patients.

=20% OF ALL PTS. (155/825)

↓

REAL BENEFIT

for 15% pts. only

CZECH MYELOMA GROUP
CMG
ČESKÁ MYELOMOVÁ SKUPINA

NEW DRUGS

NEW STRATEGIES

Mohou zásadně zmněnit prognózu 3/4 našich nemocných

CZECH MYELOMA GROUP
CMG
ČESKÁ MYELOMOVÁ SKUPINA